Meeting
2022 ASCO Annual Meeting
Circulating tumor DNA analysis and association with relapse in patients with primary refractory multiple myeloma receiving secondary salvage therapy.
Authors
Sridurga Mithraprabhu
Alfred Hospital / Monash University, Melbourne, Australia
Sridurga Mithraprabhu , John Reynolds , Rose Turner , Anna Kalff , Krystal Bergin , HANG QUACH , Tiffany Khong , Brian G. Durie , Andrew Spencer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 8037)
DOI
10.1200/JCO.2022.40.16_suppl.8037
Abstract #
8037
Poster Bd #
461
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma.
First Author: Andrew J Yee
Poster
2019 ASCO Annual Meeting
Overall survival (OS) with oral selinexor plus low dose dexamethasone (Sd) in patients with triple class refractory-multiple myeloma (TCR-MM).
First Author: Paul G. Richardson
Poster
2018 ASCO Annual Meeting
A phase II study of elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.
First Author: Andrew Jenho Yee
Poster
2018 ASCO Annual Meeting
A phase 1/2, multicenter, dose-escalation and expansion study of combination therapy with venetoclax, daratumumab, and dexamethasone (with and without bortezomib) in subjects with relapsed or refractory multiple myeloma.
First Author: Orlando Bueno